Drug Profile
Batabulin
Alternative Names: T 138067; T 67Latest Information Update: 08 Apr 2010
Price :
$50
*
At a glance
- Originator Amgen
- Class Antineoplastics; Small molecules; Sulfonamides
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Glioma; Liver cancer; Non-small cell lung cancer
Most Recent Events
- 17 Aug 2004 Tularik has been acquired and merged into Amgen
- 24 Oct 2003 Batabulin has received fast track status for liver cancer in the US
- 25 Mar 2003 Phase-III clinical trials in liver cancer in Asia (IV)